These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29409780)

  • 1. Radiotherapy of rectal cancer in elderly patients: Real-world data assessment in a decade.
    Diao P; Langrand-Escure J; Garcia MA; Espenel S; Rehailia-Blanchard A; de Lavigerie B; Vial N; de Laroche G; Vallard A; Magné N
    Dig Liver Dis; 2018 Jun; 50(6):608-616. PubMed ID: 29409780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
    Engels B; Tournel K; Everaert H; Hoorens A; Sermeus A; Christian N; Storme G; Verellen D; De Ridder M
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):142-8. PubMed ID: 22014952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer.
    Susko M; Lee J; Salama J; Thomas S; Uronis H; Hsu D; Migaly J; Willett C; Czito B; Palta M
    Ann Surg Oncol; 2016 Oct; 23(11):3609-3615. PubMed ID: 27169769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study.
    Cai G; Zhu J; Hu W; Zhang Z
    Radiat Oncol; 2014 Dec; 9():278. PubMed ID: 25497847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
    Das P; Delclos ME; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Eng C; Bedi M; Krishnan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):60-5. PubMed ID: 19695792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily reirradiation for rectal cancer in patients who have received previous pelvic radiotherapy.
    Ng MK; Leong T; Heriot AG; Ngan SY
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):512-8. PubMed ID: 23870353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.
    Kishan AU; Voog JC; Wiseman J; Cook RR; Ancukiewicz M; Lee P; Ryan DP; Clark JW; Berger DL; Cusack JC; Wo JY; Hong TS
    Br J Radiol; 2017 Aug; 90(1076):20170134. PubMed ID: 28613934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radical surgery combined with adjuvant radiotherapy for elderly patients aged over 75 years with stage II( or III( rectal cancer: a retrospective study from a single center].
    Liu W; Jin J; Li Y; Wang S; Song Y; Liu Y; Wang W; Ren H; Fang H; Li N; Tang Y; Wang X; Tang Y; Lu N; Xiao Q; Feng Y; Wang J; Deng L; Jing H; Liu X; Yu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jun; 21(6):654-659. PubMed ID: 29968240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
    Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
    Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
    Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
    Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definitive radical external beam radiotherapy for rectal cancer: evaluation of local effectiveness and risk of late small bowel damage.
    Sprawka A; Pietrzak L; Garmol D; Tyc-Szczepaniak D; Kepka L; Bujko K
    Acta Oncol; 2013 May; 52(4):816-23. PubMed ID: 22860980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.